The purpose of this study is to assess the safety and efficacy of glucocorticosteroid for treatment of drug-induced liver injury.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
80
Participants received glucocorticoids (0.4mg/kg/d po.) and hepatoprotectant for 7 days.
Participants received hepatoprotectants (i.v.gtt.) for 7 days.
Division of Gastroenterology & Hepatology,West China Hospital,Sichuan University
Chengdu, Sichuan, China
RECRUITINGpercentage of patients that AST or ALT decline 25% at day 4
AST or ALT decline 25% at day 4
Time frame: Change from Baseline ALT and AST at day4
percentage of patients that AST or ALT decline 50% at day 8
AST or ALT decline 25% at day 8
Time frame: Change from Baseline ALT and AST at day8
the time needed when TBIL decline 50%
TBIL decline 50%; time
Time frame: up to 2 weeks
incidence of side effects
infection,uncontrolled hypertension or hyperglycemia
Time frame: up to 2 years
relapse rate in 12 months after drug withdrawal
relapse rate
Time frame: 12 months after drug withdrawal
mortality in 12 months after drug withdrawal
mortality
Time frame: 12 months after drug withdrawal
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.